Xconomy | National - Business + Technology in the Exponential Economy

Archives

by in
Entry Blogger Date Location
Isis Extends Timeline on Cholesterol-Lowering Drug, FDA Delays Review of Cadence Pain Reliever, Fate Therapeutics Raises $30 Million, & More San Diego Life Sciences News Denise Gellene 11/19/09 San Diego
A Week of Woe for Genzyme, A CPR App for Your iPhone, A Better Treatment for Opioid Dependence, and More Boston-Area Life Sciences News Wade Roush 11/19/09 Boston
Genzyme Halts Development of New Kidney Drug; A “Very Significant” Bust, Analyst Says Luke Timmerman 11/18/09 Boston
Isis, Genzyme Cholesterol Drug Passes Test, But Investors Get Nervous About Liver Safety Luke Timmerman 11/17/09 San Diego
FDA Shoots Down Genzyme’s Latest Bid for Pompe Drug Approval Ryan McBride 11/16/09 Boston
Genzyme Shares Tank After FDA Discovers Bits of Steel, Rubber in Five Different Drugs Luke Timmerman 11/13/09 Boston
On-Q-ity Raises $21M in A Round for Personalized Cancer Testing Ryan McBride 11/03/09 Boston
Seattle Biotech Needs More Bars, Less University Red Tape, and the Same Daring Attitude, & Other Highlights from Seattle Life Sciences 2029 Luke Timmerman 10/21/09 Seattle
Isis CEO Vows that Cholesterol Drug, Partnered With Genzyme, Will be “Remarkable” Advance Luke Timmerman 10/21/09 San Diego
Six Tips on How to Spot a Winning Biotech, From Dendreon Co-Founder Chris Henney Luke Timmerman 10/14/09 Seattle
Public Biotechs’ Finances Foundering, Epizyme Banks $32M, Paratek Cuts Deal with Novartis, & More Boston-Area Life Sciences News Rebecca Zacks 10/09/09 Boston
Polaris Picks Immuneering, Developer of Personalized Cancer Test, as First Life Sciences Startup in Dog Patch Incubator Luke Timmerman 10/08/09 Boston
The Boston Biotech Survival Index: Big Fish Still Swimming, Minnows Getting Eaten Luke Timmerman 10/08/09 Boston
DC Matters, But Biotech Can’t Neglect City Hall David Miller 10/07/09 Seattle
Genzyme Drug Fails to Win FDA Nod Luke Timmerman 10/06/09 Boston
Former Harvard Official Tapped to Expand Tech Transfer at Brown U. Ryan McBride 10/01/09 Boston
Genzyme Faces More Setbacks, Humedica Creating a Healthcare “Census,” Pops Back as Alkermes CEO, & More Boston-Area Life Science News Ryan McBride 09/30/09 Boston
Alkermes’ Ambitious Builder, Richard Pops, Grabs Reins to Re-Ignite Growth Phase Luke Timmerman 09/28/09 Boston
Genzyme Says Supplies, Sales of Two Enzyme Drugs Will Be Even Lower Than Previously Predicted Wade Roush 09/23/09 Boston
Biogen Idec Still Pursuing Facet Acquisition, Helicos Gets $10M Reprieve, Seaside Collects $30M for Autism Drug Development, & More Boston-Area Life Sciences News Rebecca Zacks 09/23/09 Boston
Ascent Therapeutics’ Blood Cancer Drug Could Rival Genzyme’s Mozobil Ryan McBride 09/16/09 Boston
Acceleron Aims for Anemia Cure, Mascoma to Pump Out Biofuels For Chevron, Genzyme Chief to Head Boston Fed, & More Boston-Area Life Sciences News Rebecca Zacks 09/16/09 Boston
Pervasis Therapeutics Secures $10M in New Financing Ryan McBride 09/15/09 Boston
Termeer to Chair Boston Fed Reserve Ryan McBride 09/15/09 Boston
Arena Prepares to Release Big Obesity Study, Minnow Medical Goes Into ‘Commercialization Mode,’ Metabasis Hires Strategic Adviser, & More San Diego Life Sciences News Bruce V. Bigelow 09/10/09 San Diego
Ambit Biosciences, In Third Incarnation, Gears Up for Pivotal Study of Leukemia Drug Luke Timmerman 09/10/09 San Diego
Targeted Genetics Lives On, CellCyte Charged With Fraud, Theraclone Finds HIV Weakness, & More Seattle-Area Life Sciences News Luke Timmerman 09/10/09 Seattle
Targeted Genetics Survives Brush With Death, Sells Gene Therapy IP to Genzyme for $7M Luke Timmerman 09/09/09 National
Genzyme’s Woes Piling Up as FDA Panel Says Data on Leukemia Drug are Lacking Luke Timmerman 09/01/09 Boston
Another Genzyme Rival Advancing Ryan McBride 09/01/09 Boston
Page 1 of 7 next page »
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.

© 2007-2009, Xconomy, Inc. XCONOMY is a registered service mark of Xconomy, Inc. All rights reserved.
Site designed by Matthew Bouchard, produced by Andrew Koyfman, and powered by WordPress.